New Releases from NCBI BookshelfAdalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed.​Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed.

Post Content

​ 

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top